Literature DB >> 12631687

Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure.

D Thabut, V Ratziu, B Bernard-Chabert, T Poynard, Y Benhamou, V Thibault.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12631687      PMCID： PMC1773611          DOI： 10.1136/gut.52.4.614-a

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.

Authors:  D Thabut; V Thibault; Y Benhamou; B Bernard; C Aubron-Olivier; T Poynard; V Di Martino
Journal:  AIDS       Date:  2001-12-07       Impact factor: 4.177

2.  Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.

Authors:  J W Kim; H S Lee; G H Woo; J H Yoon; J J Jang; J G Chi; C Y Kim
Journal:  Clin Infect Dis       Date:  2001-07-07       Impact factor: 9.079

3.  Lamivudine resistance in chronic hepatitis B.

Authors:  M Atkins; D F Gray
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

4.  Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.

Authors:  M G Peters; G Singer; T Howard; S Jacobsmeyer; X Xiong; C S Gibbs; P Lamy; A Murray
Journal:  Transplantation       Date:  1999-12-27       Impact factor: 4.939

5.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

Authors:  Y Benhamou; M Bochet; V Thibault; V Calvez; M H Fievet; P Vig; C S Gibbs; C Brosgart; J Fry; H Namini; C Katlama; T Poynard
Journal:  Lancet       Date:  2001-09-01       Impact factor: 79.321

6.  Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus.

Authors:  P Stärkel; Y Horsmans; A Geubel; O Ciccarelli; P Goubau; J Rahier; J Lerut
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

7.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.

Authors:  Y F Liaw; R N Chien; C T Yeh; S L Tsai; C M Chu
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

8.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Authors:  N W Leung; C L Lai; T T Chang; R Guan; C M Lee; K Y Ng; S G Lim; P C Wu; J C Dent; S Edmundson; L D Condreay; R N Chien
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

9.  The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

Authors:  R A de Man; A I Bartholomeusz; H G Niesters; P E Zondervan; S A Locarnini
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

10.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245
  10 in total
  5 in total

1.  Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B.

Authors:  Shahinul Alam; Golam Azam; Golam Mustafa; Nooruddin Ahmad; Belalul Islam; Provat Kumar Podder; Mobin Khan
Journal:  Hepatol Int       Date:  2008-09-05       Impact factor: 6.047

2.  Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.

Authors:  Cyriac Abby Philips; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

3.  Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.

Authors:  Ya-Wen Yang; Chih-Yuan Lee; Rey-Heng Hu; Po-Huang Lee; Meng-Kun Tsai
Journal:  Clin Exp Nephrol       Date:  2013-04-19       Impact factor: 2.801

4.  Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.

Authors:  Yeon Seok Seo; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Jae-Seon Kim; Kwan Soo Byun; Young-Tae Bak; Chang Hong Lee
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

5.  Entecavir and lamivudine therapy for severe acute chronic hepatitis B.

Authors:  Changhong Liu; Jing Ye; Hongyu Jia; Meijuan Zhang; Hongfeng Han; Fengzhe Chen; Congkang Chen
Journal:  Exp Ther Med       Date:  2012-12-05       Impact factor: 2.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.